Trials / Unknown
UnknownNCT04340427
A Study of TQB3455 Tablets in Subjects With Advanced Malignancies
A Phase I Study of TQB3455 Tablets in Subjects With Advanced Malignancies
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a open-label, multicenter, phase I study to evaluate tolerance and pharmacokinetics of TQB3455 tablets in subjects with advanced malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3455 | TQB3455 tablets is a small molecule oral drug inhibiting IDH2 mutation. |
Timeline
- Start date
- 2020-04-10
- Primary completion
- 2021-06-30
- Completion
- 2021-12-31
- First posted
- 2020-04-09
- Last updated
- 2020-07-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04340427. Inclusion in this directory is not an endorsement.